Back to News
Market Impact: 0.28
This Small Biotech's Cancer Drug Could Reach $1.3 Billion In Peak Sales
Source: benzinga.com
Healthcare & BiotechAnalyst InsightsCompany Fundamentals
William Blair initiated bullish coverage of Zentalis Pharmaceuticals, citing potential blockbuster commercial opportunity for its lead oncology candidate, azenosertib. The positive analyst view supports the investment case for Zentalis, though the article provides no price target, clinical-data update, or revenue forecast.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
ZNTL0.72
More News
- Why Wendy’s is losing the burger wars—and is now a takeover target for Nelson Peltz
- Companies promised AI gains— here's how the payoff showed up in earnings
- FBI blames North Korea for record $6.3bn crypto heist
- Binance to resume crypto withdrawals in phases after record $6 billion hack
- AWS grows 39% and Amazon will spend even more on AI in 2027
- SpaceX loses bid to toss NAACP lawsuit over Memphis data center air pollution